Ben Derman on X: "CASSIOPEIA MRD analysis: Take a look at the top two PFS curves for Dara-VTd vs. VTd among MRD-negative patients. Doesn't seem like sustained MRD-negativity behaves the same? For
Multiple Myeloma Hub on X: "#ASCO21 | Patients treated with dara+VTd/dara achieved higher responses and MRD negativity rates. đŸ“¢Share your experience with dara+VTd! How might the CASSIOPEIA results impact other trials exploring
Die Erstlinientherapie des Multiplen Myeloms – aktueller Stand und neue Entwicklungen
Daratumumab in first-line therapy is cost-effective in transplant-eligible patients with newly diagnosed myeloma - ScienceDirect
Daratumumab maintenance after treatment with VTd w/DARA and ASCT in pts with NDMM: CASSIOPEIA Part 2 - YouTube
PDF) Prognostic value of positron emission tomography/computed tomography in transplanteligible newly diagnosed multiple myeloma patients from CASSIOPEIA: the CASSIOPET study
Daratumumab maintenance after treatment with VTd w/DARA and ASCT in pts with NDMM: CASSIOPEIA Part 2
Best Practice for Newly Diagnosed Myeloma Patients Eligible for Transplant: How Can We Optimize Therapy?
Ben Derman on X: "CASSIOPEIA MRD analysis: Take a look at the top two PFS curves for Dara-VTd vs. VTd among MRD-negative patients. Doesn't seem like sustained MRD-negativity behaves the same? For
ROLE OF DARATUMUMAB IN NEWLY DIAGNOSED MULTIPLE MYELOMA.pptx
CASSIOPEIA - Dara-VTd - Multiple Myeloma Clinical Trials
EHA Library - The official digital education library of European Hematology Association (EHA)
Vantaggi dall'aggiunta di daratumumab a VTd nei pazienti con MM eleggibili al trapianto - Ematoinfo
Beyond the Congress Induction Therapy
A20-15 - Daratumumab - Extract of dossier assessment - Version 1.0
Multiple Myeloma Hub on X: "CONGRESS | #IMW2019 | Pieter Sonneveld, @erasmusmc, presents a subgroup analysis from the CASSIOPEIA trial of high-risk patients based on cytogenetics and ISS stage disease. Dara-VTD gave
Daratumumab (DARA) with Bortezomib, Thalidomide, and Dexamethasone (VTd) in Transplant-Eligible Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM): Analysis of Minimal Residual Disease (MRD) Negativity in Cassiopeia Part 1 and Part 2 -
Ben Derman on X: "CASSIOPEIA MRD analysis: Take a look at the top two PFS curves for Dara-VTd vs. VTd among MRD-negative patients. Doesn't seem like sustained MRD-negativity behaves the same? For
Impact of VTD or VRD induction on stem-cell collection a Impact of VTD... | Download Scientific Diagram
Treatment emergent peripheral neuropathy in the CASSIOPEIA trial | Haematologica
Addition of daratumumab to treatment is beneficial in newly diagnosed myeloma patients - BJH
When and How to Treat Relapsed Multiple Myeloma
Vincent Rajkumar on X: "CASSIOPEIA trial maintenance results in myeloma: Main takeaway is that daratumumab maintenance provided ZERO benefit if daratumumab was given as induction/consolidation This PFS curve (blue versus yellow line)
Treatment emergent peripheral neuropathy in the CASSIOPEIA trial | Haematologica
